Piper Jaffray Starts Nexvet Biopharma (NVET) at Overweight
Tweet Send to a Friend
Piper Jaffray initiates coverage on Nexvet Biopharma (NASDAQ: NVET) with a Overweight rating and a price target of $17.00.Analyst Kevin ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE